Concurrent outbreaks of circulating vaccine-derived poliovirus types 1 and 2 affecting the Republic of the Philippines and Malaysia, 2019–2021
Authors:
- Snider, Cynthia J.
- Boualam, Liliane
- Tallis, Graham
- Takashima, Yoshihiro
- Abeyasinghe, Rabindra
- Lo, Ying-Ru
- Grabovac, Varja
- Avagyan, Tigran
- Aslam, Syeda Kanwal
- Eltayeb, Abu Obeida
- Aung, Khin Devi
- Wang, Xiaojun
- Shrestha, Achyut
- Ante-Orozco, Carla
- Silva, Maria Wilda T.
- Lapastora-Sucaldito, Nemia
- Apostol, Lea Necitas G.
- Jikal, Muhammad Bin Hj.
- Miraj, Waheed
- Lodhi, Faisal
- Kim, Hyung Joon
- Rusli, Norhayati
- Thorley, Bruce R.
- Kaye, Matthew B.
- Nishimura, Yorihiro
- Arita, Minetaro
- Sani, Jamiatul Aida Md.
- Rundi, Christina
- Feldon, Keith
Details:
Vaccine, Volume 41, 2023-04-06
Article Link: Click here
Concurrent outbreaks of circulating vaccine-derived poliovirus serotypes 1 and 2 (cVDPV1, cVDPV2) were confirmed in the Republic of the Philippines in September 2019 and were subsequently confirmed in Malaysia by early 2020. There is continuous population subgroup movement in specific geographies between the two countries. Outbreak response efforts focused on sequential supplemental immunization activities with monovalent Sabin strain oral poliovirus vaccine type 2 (mOPV2) and bivalent oral poliovirus vaccines (bOPV, containing Sabin strain types 1 and 3) as well as activities to enhance poliovirus surveillance sensitivity to detect virus circulation. A total of six cVDPV1 cases, 13 cVDPV2 cases, and one immunodeficiency-associated vaccine-derived poliovirus type 2 case were detected, and there were 35 cVDPV1 and 31 cVDPV2 isolates from environmental surveillance sewage collection sites. No further cVDPV1 or cVDPV2 have been detected in either country since March 2020. Response efforts in both countries encountered challenges, particularly those caused by the global COVID-19 pandemic. Important lessons were identified and could be useful for other countries that experience outbreaks of concurrent cVDPV serotypes.